

Maroeska te Loo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/626195/publications.pdf>

Version: 2024-02-01

40
papers

1,195
citations

394421

19
h-index

377865

34
g-index

40
all docs

40
docs citations

40
times ranked

1918
citing authors

#	ARTICLE	IF	CITATIONS
1	Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML01. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27605.	1.5	26
2	Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE) Tj ETQq0 0 0sgBT /Overlock 10 Tf		
3	Efficacy and safety of recombinant <i>E. coli</i> asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27083.	1.5	18
4	Pediatric Diamond-Blackfan anemia in the Netherlands: An overview of clinical characteristics and underlying molecular defects. <i>European Journal of Haematology</i> , 2018, 100, 163-170.	2.2	19
5	Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients. <i>Haematologica</i> , 2017, 102, 552-561.	3.5	14
6	The role of germline variants in chemotherapy outcome in brain tumors: a systematic review of pharmacogenetic studies. <i>Pharmacogenomics</i> , 2017, 18, 501-513.	1.3	3
7	TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial. <i>BMC Pediatrics</i> , 2017, 17, 122.	1.7	22
8	The role of pharmacogenetics in the treatment of osteosarcoma. <i>Drug Discovery Today</i> , 2016, 21, 1775-1786.	6.4	58
9	Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 243-247.	1.5	42
10	Independent development of lymphoid and histiocytic malignancies from a shared early precursor. <i>Leukemia</i> , 2016, 30, 955-958.	7.2	13
11	Serum Shiga toxin 2 values in patients during acute phase of diarrhoea-associated haemolytic uraemic syndrome. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2015, 104, e564-8.	1.5	19
12	A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment. <i>Clinical Cancer Research</i> , 2015, 21, 3436-3441.	7.0	34
13	High-Quality Genotyping Data from Formalin-Fixed, Paraffin-Embedded Tissue on the Drug Metabolizing Enzymes and Transporters Plus Array. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 4-9.	2.8	14
14	Is there a role for the MTHFR 677C>T and 1298A>C polymorphisms in methotrexate-induced liver toxicity?. <i>Pharmacogenomics</i> , 2014, 15, 1401-1403.	1.3	10
15	The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer. <i>Pharmacogenomics Journal</i> , 2014, 14, 115-119.	2.0	27
16	A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics. <i>Blood</i> , 2014, 124, 3027-3029.	1.4	12
17	A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. <i>Blood</i> , 2014, 123, 2026-2033.	1.4	177
18	Influence of Genetic Variants in TPMT and COMT Associated with Cisplatin Induced Hearing Loss in Patients with Cancer: Two New Cohorts and a Meta-Analysis Reveal Significant Heterogeneity between Cohorts. <i>PLoS ONE</i> , 2014, 9, e115869.	2.5	47

#	ARTICLE	IF	CITATIONS
19	The role of AXL and the <i>in vitro</i> activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma. <i>Oncotarget</i> , 2014, 5, 12753-12768.	1.8	46
20	Survival Trends and Long-Term Toxicity in Pediatric Patients with Osteosarcoma. <i>Sarcoma</i> , 2012, 2012, 1-5.	1.3	33
21	A novel Dutch mutation in <i>UNC13D</i> reveals an essential role of the C2B domain in munc13 function. <i>Pediatric Blood and Cancer</i> , 2012, 58, 598-605.	1.5	7
22	Age as prognostic factor in patients with osteosarcoma. <i>Bone</i> , 2011, 49, 1173-1177.	2.9	33
23	Rapid-growing Tumor of the Cheek Mimicking a Malignant Tumor. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, 113-115.	0.6	6
24	Taqman genotyping assays can be used on decalcified and paraffin-embedded tissue from patients with osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2011, 56, 35-38.	1.5	14
25	Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1853-1856.	3.0	56
26	Relevance of germ-line genetic variations for treatment response in pediatric osteosarcoma patients. <i>Journal of Clinical Oncology</i> , 2011, 29, 9518-9518.	1.6	0
27	Polymorphisms and mutations of human Tmprss6 in iron deficiency anemia. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 44, 16-21.	1.4	56
28	Association of a genetic variant in the <i>ABCC2</i> gene with high methotrexate plasma concentrations in pediatric malignancies. <i>Journal of Clinical Oncology</i> , 2010, 28, 9522-9522.	1.6	3
29	Genetic variants in <i>MDR1</i> and <i>CYP3A5</i> and vincristine toxicity in children with acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 9526-9526.	1.6	1
30	No treatment related mortality in patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) in Dutch Childhood Oncology Group protocols ALL-7 and ALL-8. <i>Journal of Clinical Oncology</i> , 2008, 26, 10004-10004.	1.6	0
31	Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 749-755.	0.7	31
32	Shiga toxin-1 affects nitric oxide production by human glomerular endothelial and mesangial cells. <i>Pediatric Nephrology</i> , 2006, 21, 1815-1823.	1.7	15
33	Prognostic Significance of Blasts in the Cerebrospinal Fluid Without Pleiocytosis or a Traumatic Lumbar Puncture in Children With Acute Lymphoblastic Leukemia: Experience of the Dutch Childhood Oncology Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 2332-2336.	1.6	96
34	The Effect of Flavoring Oral Rehydration Solution on its Composition and Palatability. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2004, 39, 545-548.	1.8	14
35	Decrease of thrombomodulin contributes to the procoagulant state of endothelium in hemolytic uremic syndrome. <i>Pediatric Nephrology</i> , 2003, 18, 1066-1068.	1.7	34
36	Production of hemopexin by TNF- α stimulated human mesangial cells. <i>Kidney International</i> , 2003, 63, 1681-1686.	5.2	31

#	ARTICLE	IF	CITATIONS
37	Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF- κ B dependent up-regulation of IL-8 and MCP-11. <i>Kidney International</i> , 2002, 62, 846-856.	5.2	105
38	Anticardiolipin antibodies in D+ hemolytic uremic syndrome. <i>Pediatric Nephrology</i> , 2002, 17, 1042-1046.	1.7	6
39	Vero Cytotoxin Binding to Polymorphonuclear Leukocytes among Households with Children with Hemolytic Uremic Syndrome. <i>Journal of Infectious Diseases</i> , 2001, 184, 446-450.	4.0	24
40	Detection of Apoptosis in Kidney Biopsies of Patients with D+ Hemolytic Uremic Syndrome. <i>Pediatric Research</i> , 2001, 49, 413-416.	2.3	17